<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04777435</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL19_0075</org_study_id>
    <nct_id>NCT04777435</nct_id>
  </id_info>
  <brief_title>Therapeutic Orientation Test in Thrombotic Microangiopathy</brief_title>
  <acronym>TOTEM</acronym>
  <official_title>Therapeutic Orientation Test in Thrombotic Microangiopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Haemolytic and Uraemic Syndrome (HUS) is a serious disease requiring rapid diagnosis and&#xD;
      management. The atypical HUS diagnosis has been greatly improved by anti-CS antibody&#xD;
      (Eculizumab) wich block alternative complement pathway activation. To rise treatment success,&#xD;
      Eculizumab introduction should be as early as possible. In some secondary HUS (infection,&#xD;
      drugsâ€¦) complement is also involved as &quot;second-hit&quot;.&#xD;
&#xD;
      To date, there is no tool to confirm complement involvement in a HUS at diagnosis stage. This&#xD;
      study suggest to evaluate a therapeutic orientation test, in order to determine the&#xD;
      complement implication in HUS diagnosis. The test evaluates the complement deposits on&#xD;
      endothelial cell surface in vitro, compared to a normal human serum.&#xD;
&#xD;
      In order to determine the test performance, first the positive or negative results will be&#xD;
      compared to the HUS clinical evolution, treated or not by the clinician with Eculizumab.&#xD;
      Second, the test results will be compared to the presence of alternative complement pathway&#xD;
      regulation abnormalities.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2021</start_date>
  <completion_date type="Anticipated">April 3, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 3, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Therapeutic orientation test sensitivity</measure>
    <time_frame>Through study completion, an average of 3 years.</time_frame>
    <description>The proportion of patients testing positive among those receiving a relevant Eculizumab treatment ( TMA resolution with treatment or presence of abnormalities in alternative complement pathway.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Therapeutic orientation test specificity</measure>
    <time_frame>Through study completion, an average of 3 years.</time_frame>
    <description>The proportion of patients testing negative among patients who did not receive Eculizumab treatment.(TMA resolution without treatment or therapeutic failure with Eculizumab).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Untreated test positive patients</measure>
    <time_frame>Through study completion, an average of 3 years.</time_frame>
    <description>The proportion of patients with positive test but untreated by Eculizumab, and who therefore could have benefited from treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Thrombotic Micro-angiopathy</condition>
  <arm_group>
    <arm_group_label>Patients with Thrombotic micro-angiopathy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Therapeutic orientation test for TMA</intervention_name>
    <description>Therapeutic orientation test for TMA performed on blood sample at inclusion, first visit at 1 month and last visit at 6 months.</description>
    <arm_group_label>Patients with Thrombotic micro-angiopathy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        TMA with:&#xD;
&#xD;
          -  mechanic haemolytic anemia, undetectable haptoglobin, LDH&gt;1.5*LNS&#xD;
&#xD;
          -  thrombopenia&#xD;
&#xD;
          -  acute kidney injury TMA on native kidney or in post-transplantation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  DIVC patients&#xD;
&#xD;
          -  plasma exchange during 1 month before sample collection&#xD;
&#xD;
          -  treatment by Eculizumab before sample collection&#xD;
&#xD;
          -  no consent&#xD;
&#xD;
          -  not beneficiary of a social security&#xD;
&#xD;
          -  pregnancy or breastfeeding&#xD;
&#xD;
          -  patient Under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Moglie LE QUNITREC-DONNETTE, Professor</last_name>
    <phone>467330996</phone>
    <phone_ext>+33</phone_ext>
    <email>m-lequintrec-donnette@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Montpellier University Hospital</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moglie LE QUINTREC-DONNETTE, Pr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2021</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nephrology</keyword>
  <keyword>Complement</keyword>
  <keyword>Thrombotic micro-angiopathy</keyword>
  <keyword>Diagnostic</keyword>
  <keyword>Haemolytic and Uraemic Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombotic Microangiopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

